SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Gilda Radner Synthetic CCD

PatientGilda Radner
Date of birth1986-06-28
IdentifiersMRN HR-ML026-SYN; SSN (made up) 000-26-8821
Document date2026-11-01
AuthorDelia Marchand, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Four weeks of bloating, early fullness and pelvic pain in a woman of 39: symptom index, pelvic examination, CA-125, and same-week imaging. Concerns: Four weeks of bloating that makes her clothes tight, feeling full after a few bites, a dull ache low in the abdomen and pelvis, and passing urine more often, on most days; she has been more tired than usual for longer than that; Afraid this is cancer: her father died of a brain tumor and ovarian cancer runs in her family; she wants to be taken seriously and told plainly. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery40 mg under the skin once daily for 28 daysSubcutaneous route2026-04-21 to 2026-05-18completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a dayTwo tablets every 6 hours as neededOral route2026-04-21 to 2026-05-05completedS
Carboplatin 10 mg/mL injection, 610 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2026-05-12 to 2026-08-25completedS
Paclitaxel 6 mg/mL injection, 275 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidineDay 1 every 21 days for six cyclesIntravenous route2026-05-12 to 2026-08-25completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as needed for nauseaOral route2026-05-12activeS
Olaparib 150 mg oral tablet, two tablets (300 mg) by mouth twice daily with food, as maintenance for up to two yearsTwo tablets twice daily with foodOral route2026-09-15activeS

Procedures

ProcedureDatesStatusEvidence
Transvaginal ultrasound of the pelvis: a 9.2 cm solid and cystic right adnexal mass and a 5.1 cm solid left adnexal mass, both with irregular solid parts and strong internal blood flow; moderate ascites; uterus normal (O-RADS 5)2026-04-07 to 2026-04-07completedS
CT of the chest, abdomen and pelvis with contrast: bilateral adnexal masses, moderate ascites, omental caking up to 4 cm, a 1.2 cm nodule on the right hemidiaphragm, and small pelvic peritoneal nodules; no enlarged lymph nodes, no liver or lung lesion, and no pleural effusion2026-04-08 to 2026-04-08completedS
Ultrasound-guided core needle biopsy of the omentum: high-grade serous carcinoma, PAX8 and WT1 positive, p53 aberrant (Mullerian origin); CK7 positive, CK20 negative2026-04-10 to 2026-04-10completedS
Primary cytoreductive surgery by gynecologic oncology: laparotomy, total abdominal hysterectomy with bilateral salpingo-oophorectomy, total omentectomy, stripping of the right hemidiaphragm peritoneum, and excision of pelvic peritoneal nodules, with no visible residual disease (complete gross resection); lymph nodes not removed because none were enlarged. Pathology: high-grade serous carcinoma of both ovaries with serous tubal intraepithelial carcinoma in the right fallopian tube; omental deposit 4.5 cm, diaphragm 1.3 cm; ascitic fluid positive; pT3c, FIGO stage IIIC2026-04-21 to 2026-04-21completedS
Genetic counseling before germline testing: three-generation pedigree, Ashkenazi Jewish ancestry, the meaning of positive, negative and uncertain results for her and for her blood relatives, and consent for a multigene panel2026-04-14 to 2026-04-14completedS
Advance care planning conversation, about 20 minutes2026-10-13 to 2026-10-13completedS
CT of the chest, abdomen and pelvis with contrast at the end of chemotherapy: no ascites, no peritoneal or omental nodule, no enlarged lymph node, and no liver or lung lesion; expected postoperative changes (no evidence of disease)2026-09-08 to 2026-09-08completedS

Immunizations

DateVaccineStatusEvidence
2021-09-20Tdap vaccinecompletedS
2026-10-13Influenza vaccine, this season (inactivated)completedS
2026-10-13COVID-19 mRNA vaccine, this season's formulacompletedS
2026-10-13Pneumococcal conjugate vaccine (PCV20)completedS
2026-10-13Recombinant zoster vaccine, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1975 to 1980Bulimia during her television career in the late 1970s, which she later wrote about; no treatment recorded in the cited sourceD (CLM-0008)
About 1985Two miscarriages and an unsuccessful round of in vitro fertilization in her late thirtiesD (CLM-0007)

Family History

RelativeConditionAge at deathEvidence
fatherBrain cancer; died when she was fourteenD (CLM-0003)
grandmotherOvarian cancer; side of the family not recorded in the cited sourceD (CLM-0003)
auntOvarian cancer; side of the family not recorded in the cited sourceD (CLM-0003)
cousinOvarian cancer; side of the family not recorded in the cited sourceD (CLM-0003)

Health Concerns

ConcernStatusEvidence
Four weeks of bloating that makes her clothes tight, feeling full after a few bites, a dull ache low in the abdomen and pelvis, and passing urine more often, on most days; she has been more tired than usual for longer than thatactiveS
Afraid this is cancer: her father died of a brain tumor and ovarian cancer runs in her family; she wants to be taken seriously and told plainlyactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 10.6 on 2026-10-13; Leukocytes [#/volume] in Blood by Automated count 4.2 on 2026-10-13; Platelets [#/volume] in Blood by Automated count 182 on 2026-10-13; Sodium [Moles/volume] in Serum or Plasma 136 on 2026-04-06; Potassium [Moles/volume] in Serum or Plasma 4.2 on 2026-04-06; Creatinine [Mass/volume] in Serum or Plasma 0.69 on 2026-09-15; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 113 on 2026-09-15; Glucose [Mass/volume] in Serum or Plasma 88 on 2026-04-06; Calcium [Mass/volume] in Serum or Plasma 9.4 on 2026-04-06; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 on 2026-09-15; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 on 2026-05-12; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 84 on 2026-04-06; Bilirubin.total [Mass/volume] in Serum or Plasma 0.4 on 2026-09-15; Albumin [Mass/volume] in Serum or Plasma 3.7 on 2026-05-12; Cancer Ag 125 [Units/volume] in Serum or Plasma 9 on 2026-09-15; Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 1.6 on 2026-04-06; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-04-06; Pain severity - 0-10 verbal numeric rating [Score] - Reported 2 on 2026-05-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 2026-10-13; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 8 on 2026-04-14; Neutrophils [#/volume] in Blood by Automated count 2.4 on 2026-10-13; Magnesium [Mass/volume] in Serum or Plasma 1.7 on 2026-07-14; Cholesterol [Mass/volume] in Serum or Plasma 186 on 2026-10-13; Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 on 2026-10-13; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 108 on 2026-10-13; Triglyceride [Mass/volume] in Serum or Plasma 98 on 2026-10-13; Total score [AUDIT-C] 1 on 2026-10-13 [S]

Strengths and supports: Supports: her spouse and close friends from work; humor is how she copes. She decides who is told about her health [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Persistent bloating with tightness of her clothes, feeling full after a few bites, a dull lower abdominal and pelvic ache, and passing urine more often, on most days for about four weeks, in a woman of 39: the ovarian cancer symptom index is positive. Examination: a distended abdomen with shifting dullness and a firm, fixed, irregular mass in the right adnexa. Suspected ovarian cancer; transvaginal ultrasound, CT, CA-125 and gynecologic oncology review booked within the weekresolvedconfirmed R19.00S — Synthetic presenting problem linked to her documented abdominal symptoms; superseded by the diagnosis at the gynecologic oncology consultation.
High-grade serous carcinoma of both ovaries (Mullerian origin), diagnosed by image-guided omental core biopsy (PAX8 and WT1 positive, p53 aberrant), with bilateral adnexal masses, ascites, omental and diaphragmatic disease on CT: clinical FIGO stage IIIC; synthetic modern detail linked to her documented ovarian canceractiveconfirmed C56.3S — Synthetic histology and stage; the documented diagnosis was stage IV ovarian cancer (D).
Peritoneal and omental metastases of the ovarian cancer, with ascitesactiveconfirmed C78.6S — Synthetic extent of disease on CT and biopsy.
Family history of ovarian cancer in three relatives (her grandmother, an aunt, and a cousin) in a woman of Ashkenazi Jewish ancestry; no genetic testing in the family is knownactiveconfirmed Z80.41S — Synthetic coding of her documented family history; the basis for genetic counseling.
Acute viral upper respiratory infection on day 8 of the second chemotherapy cycle: two days of sore throat, runny nose and a dry cough, without fever; rapid influenza and COVID-19 tests negative; resolvedresolvedconfirmed J06.9S — Synthetic acute infection; not a historical claim.
Symptomatic surgical menopause after bilateral salpingo-oophorectomy at 39: hot flashes and night sweatsactiveconfirmed E89.41S — Synthetic consequence of the synthetic operation.
Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes and fingertips, grade 1 (sensory only, no effect on daily activities)activeconfirmed G62.0S — Synthetic common effect of paclitaxel.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-06Hemoglobin [Mass/volume] in Blood12.4g/dL11.6-15 g/dLNormalS
2026-04-06Leukocytes [#/volume] in Blood by Automated count7.810*3/uL4-11 10*3/uLNormalS
2026-04-06Platelets [#/volume] in Blood by Automated count41210*3/uL150-400 10*3/uLHighS
2026-04-06Sodium [Moles/volume] in Serum or Plasma136mmol/L135-145 mmol/LNormalS
2026-04-06Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-04-06Creatinine [Mass/volume] in Serum or Plasma0.72mg/dL0.59-1.04 mg/dLNormalS
2026-04-06Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M109mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-06Glucose [Mass/volume] in Serum or Plasma88mg/dL70-99 mg/dLNormalS
2026-04-06Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
2026-04-06Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-35 U/LNormalS
2026-04-06Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-35 U/LNormalS
2026-04-06Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma84U/L35-105 U/LNormalS
2026-04-06Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-04-06Albumin [Mass/volume] in Serum or Plasma3.6g/dL3.5-5 g/dLNormalS
2026-04-06Cancer Ag 125 [Units/volume] in Serum or Plasma1240U/mL<=35 U/mLHighS
2026-04-06Carcinoembryonic Ag [Mass/volume] in Serum or Plasma1.6ng/mL<=3 ng/mLNormalS
2026-04-06Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-04-06Pain severity - 0-10 verbal numeric rating [Score] - Reported5{score}S
2026-04-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
2026-04-14Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S
2026-05-12Hemoglobin [Mass/volume] in Blood10.9g/dL11.6-15 g/dLLowS
2026-05-12Leukocytes [#/volume] in Blood by Automated count6.910*3/uL4-11 10*3/uLNormalS
2026-05-12Neutrophils [#/volume] in Blood by Automated count4.210*3/uL1.5-7.7 10*3/uLNormalS
2026-05-12Platelets [#/volume] in Blood by Automated count35610*3/uL150-400 10*3/uLNormalS
2026-05-12Creatinine [Mass/volume] in Serum or Plasma0.68mg/dL0.59-1.04 mg/dLNormalS
2026-05-12Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M114mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-05-12Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L7-35 U/LNormalS
2026-05-12Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L8-35 U/LNormalS
2026-05-12Bilirubin.total [Mass/volume] in Serum or Plasma0.4mg/dL0.1-1.2 mg/dLNormalS
2026-05-12Albumin [Mass/volume] in Serum or Plasma3.7g/dL3.5-5 g/dLNormalS
2026-05-12Magnesium [Mass/volume] in Serum or Plasma1.9mg/dL1.7-2.2 mg/dLNormalS
2026-05-12Cancer Ag 125 [Units/volume] in Serum or Plasma188U/mL<=35 U/mLHighS
2026-05-12Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
2026-05-12Pain severity - 0-10 verbal numeric rating [Score] - Reported2{score}S
2026-06-09Hemoglobin [Mass/volume] in Blood10.6g/dL11.6-15 g/dLLowS
2026-06-09Leukocytes [#/volume] in Blood by Automated count2.910*3/uL4-11 10*3/uLLowS
2026-06-09Neutrophils [#/volume] in Blood by Automated count1.310*3/uL1.5-7.7 10*3/uLLowS
2026-06-09Platelets [#/volume] in Blood by Automated count14210*3/uL150-400 10*3/uLLowS
2026-07-14Hemoglobin [Mass/volume] in Blood10.3g/dL11.6-15 g/dLLowS
2026-07-14Leukocytes [#/volume] in Blood by Automated count4.110*3/uL4-11 10*3/uLNormalS
2026-07-14Neutrophils [#/volume] in Blood by Automated count1.910*3/uL1.5-7.7 10*3/uLNormalS
2026-07-14Platelets [#/volume] in Blood by Automated count18810*3/uL150-400 10*3/uLNormalS
2026-07-14Creatinine [Mass/volume] in Serum or Plasma0.7mg/dL0.59-1.04 mg/dLNormalS
2026-07-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M113mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-35 U/LNormalS
2026-07-14Bilirubin.total [Mass/volume] in Serum or Plasma0.4mg/dL0.1-1.2 mg/dLNormalS
2026-07-14Magnesium [Mass/volume] in Serum or Plasma1.7mg/dL1.7-2.2 mg/dLNormalS
2026-07-14Cancer Ag 125 [Units/volume] in Serum or Plasma21U/mL<=35 U/mLNormalS
2026-07-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-09-15Hemoglobin [Mass/volume] in Blood11.2g/dL11.6-15 g/dLLowS
2026-09-15Leukocytes [#/volume] in Blood by Automated count4.810*3/uL4-11 10*3/uLNormalS
2026-09-15Neutrophils [#/volume] in Blood by Automated count2.610*3/uL1.5-7.7 10*3/uLNormalS
2026-09-15Platelets [#/volume] in Blood by Automated count21410*3/uL150-400 10*3/uLNormalS
2026-09-15Creatinine [Mass/volume] in Serum or Plasma0.69mg/dL0.59-1.04 mg/dLNormalS
2026-09-15Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M113mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-09-15Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L7-35 U/LNormalS
2026-09-15Bilirubin.total [Mass/volume] in Serum or Plasma0.4mg/dL0.1-1.2 mg/dLNormalS
2026-09-15Cancer Ag 125 [Units/volume] in Serum or Plasma9U/mL<=35 U/mLNormalS
2026-09-15Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-10-13Hemoglobin [Mass/volume] in Blood10.6g/dL11.6-15 g/dLLowS
2026-10-13Leukocytes [#/volume] in Blood by Automated count4.210*3/uL4-11 10*3/uLNormalS
2026-10-13Neutrophils [#/volume] in Blood by Automated count2.410*3/uL1.5-7.7 10*3/uLNormalS
2026-10-13Platelets [#/volume] in Blood by Automated count18210*3/uL150-400 10*3/uLNormalS
2026-10-13Cholesterol [Mass/volume] in Serum or Plasma186mg/dL<=200 mg/dLNormalS
2026-10-13Cholesterol in HDL [Mass/volume] in Serum or Plasma58mg/dL>=50 mg/dLNormalS
2026-10-13Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation108mg/dL<=129 mg/dLNormalS
2026-10-13Triglyceride [Mass/volume] in Serum or Plasma98mg/dL<=149 mg/dLNormalS
2026-10-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S
2026-10-13Total score [AUDIT-C]1{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-04-06Body height160cmS
2026-04-06Body weight58.5kgS
2026-04-06Body mass index (BMI) [Ratio]22.9kg/m2S
2026-04-06Systolic blood pressure118mm[Hg]S
2026-04-06Diastolic blood pressure74mm[Hg]S
2026-04-06Heart rate92/minS
2026-04-06Respiratory rate16/minS
2026-04-06Body temperature36.9CelS
2026-04-06Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-04-14Body height160cmS
2026-04-14Body weight58.9kgS
2026-04-14Body mass index (BMI) [Ratio]23kg/m2S
2026-04-14Systolic blood pressure122mm[Hg]S
2026-04-14Diastolic blood pressure78mm[Hg]S
2026-04-14Heart rate96/minS
2026-04-14Respiratory rate16/minS
2026-04-14Body temperature36.8CelS
2026-04-14Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-05-12Body height160cmS
2026-05-12Body weight55.2kgS
2026-05-12Body mass index (BMI) [Ratio]21.6kg/m2S
2026-05-12Systolic blood pressure112mm[Hg]S
2026-05-12Diastolic blood pressure70mm[Hg]S
2026-05-12Heart rate84/minS
2026-05-12Respiratory rate14/minS
2026-05-12Body temperature36.7CelS
2026-05-12Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-07-14Body height160cmS
2026-07-14Body weight55.9kgS
2026-07-14Body mass index (BMI) [Ratio]21.8kg/m2S
2026-07-14Systolic blood pressure110mm[Hg]S
2026-07-14Diastolic blood pressure70mm[Hg]S
2026-07-14Heart rate80/minS
2026-07-14Respiratory rate14/minS
2026-07-14Body temperature36.6CelS
2026-07-14Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-09-15Body height160cmS
2026-09-15Body weight56.8kgS
2026-09-15Body mass index (BMI) [Ratio]22.2kg/m2S
2026-09-15Systolic blood pressure114mm[Hg]S
2026-09-15Diastolic blood pressure72mm[Hg]S
2026-09-15Heart rate76/minS
2026-09-15Respiratory rate14/minS
2026-09-15Body temperature36.6CelS
2026-09-15Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-06-09Body height160cmS
2026-06-09Body weight55.8kgS
2026-06-09Body mass index (BMI) [Ratio]21.8kg/m2S
2026-06-09Systolic blood pressure108mm[Hg]S
2026-06-09Diastolic blood pressure68mm[Hg]S
2026-06-09Heart rate88/minS
2026-06-09Respiratory rate16/minS
2026-06-09Body temperature37.5CelS
2026-06-09Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-13Body height160cmS
2026-10-13Body weight57.2kgS
2026-10-13Body mass index (BMI) [Ratio]22.3kg/m2S
2026-10-13Systolic blood pressure112mm[Hg]S
2026-10-13Diastolic blood pressure70mm[Hg]S
2026-10-13Heart rate74/minS
2026-10-13Respiratory rate14/minS
2026-10-13Body temperature36.6CelS
2026-10-13Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
2026-04-06Four weeks of bloating, early fullness and pelvic pain in a woman of 39: symptom index, pelvic examination, CA-125, and same-week imagingfinishedS
2026-04-14Biopsy result: ovarian cancer; gynecologic oncology consultation, genetic counseling, and preparation for surgeryfinishedS
2026-05-12Review three weeks after cytoreductive surgery: pathology, genetic results, and the first cycle of chemotherapyfinishedS
2026-07-14Midpoint of chemotherapy: CA-125, blood counts, neuropathy, and menopausal symptomsfinishedS
2026-09-15End of chemotherapy: CT and CA-125 response, and the start of olaparib maintenancefinishedS
2026-06-09Same-day sick visit for a cold during chemotherapyfinishedS
2026-10-13Periodic adult preventive visit after ovarian cancer treatmentfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Urgent gynecologic oncology consultation for a suspected ovarian cancer, before any surgery, to confirm the diagnosis and plan primary treatmentcompletedGL-NCCN-OVARIAN-2026, GL-ACOG-CO716-2017S
At the first visit: the ovarian cancer symptom index, an abdominal and pelvic examination, CA-125 with CEA, blood count and chemistry, and a urine pregnancy test; transvaginal ultrasound and CT of the chest, abdomen and pelvis within the week, and image-guided biopsy if the scan shows disease outside the pelviscompletedGL-GOFF-SI-2007, GL-ACOG-CO716-2017, GL-NCCN-OVARIAN-2026S
Genetic counseling and germline multigene panel testing (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 and the Lynch syndrome genes), as for every woman with epithelial ovarian cancer, and tumor testing for BRCA1 and BRCA2 and homologous recombination deficiency on the surgical specimen; if a germline variant is found, a family letter offering cascade testing to blood relativescompletedGL-ASCO-OVGERM-2020, GL-NCCN-OVARIAN-2026S
Primary cytoreductive surgery by gynecologic oncology aiming for no visible residual disease, with enoxaparin for four weeks after the operationcompletedGL-NCCN-OVARIAN-2026, GL-ASCO-VTE-2023S
Carboplatin (AUC 5) and paclitaxel 175 mg/m2 every three weeks for six cycles, starting three weeks after surgery, after hepatitis B, hepatitis C and HIV screening; a three-drug antiemetic regimen on each treatment day; blood counts, kidney function and magnesium before each cycle; CA-125 each cycle; and neuropathy checks at every visitcompletedGL-NCCN-OVARIAN-2026, GL-ASCO-ANTIEMETIC-2020, GL-ASCO-CIPN-2020, GL-ASCO-HBV-2020S
Olaparib 300 mg twice daily as maintenance for two years after a complete response to platinum chemotherapy, chosen because the tumor carries a BRCA1 pathogenic variant; blood count monthly for the first year, with checks for fatigue, nausea, breathlessness and new coughcompletedGL-ASCO-PARP-2020, GL-NCCN-OVARIAN-2026S
Surgical menopause: symptom review at each visit, non-hormonal measures, a discussion of menopausal hormone therapy at the end of treatment, and a baseline bone density scancompletedGL-NCCN-OVARIAN-2026, GL-SGO-SURV-2017S
Distress and depression screening at each visit, plain information, a cancer support community group, and survivorship care after treatment: a visit every three months for two years with examination and CA-125, and imaging only for symptoms or a rising CA-125completedGL-SGO-SURV-2017, GL-NCCN-OVARIAN-2026S

Goals

GoalTargetStatusOutcomeProvenance
Tissue diagnosis and gynecologic oncology plan within two weeks of presentation2026-04-14completedUltrasound, CT and biopsy within four days; diagnosis and consultation on the eighth dayS
Cytoreductive surgery with no visible residual disease within three weeks of diagnosis2026-05-12completedComplete gross resection one week after the diagnosisS
Six cycles of carboplatin and paclitaxel every three weeks without a delay of more than one week2026-09-15completedSix cycles completed on schedule; CT shows no evidence of disease and CA-125 is 9S
Germline and tumor genetic results available before the maintenance decision2026-09-15completedGermline panel negative; tumor BRCA1 pathogenic variant; olaparib startedS
PHQ-9 below 10 throughout treatment, with a peer-support connection2026-09-15completedPHQ-9 between 3 and 7; attends a cancer support community groupS

Functional Status

Mental Status